The Claim
Efavirenz inhibits mitochondrial complex I activity in isolated mouse liver mitochondria with an IC50 of approximately 30 μM, and this inhibition alone does not cause hepatocyte injury but primes cells for toxicity when combined with isoniazid.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A drug called efavirenz can block a key energy process in mouse liver cells at a specific dose, and while it doesn’t hurt the cells by itself, it makes them much more likely to get damaged when combined with another drug called isoniazid.
See the scientific wording
Efavirenz inhibits mitochondrial complex I activity in isolated mouse liver mitochondria with an IC50 of approximately 30 μM, and this inhibition alone does not cause hepatocyte injury but primes cells for toxicity when combined with isoniazid.
What the research says
1 studyEfavirenz alone doesn't hurt liver cells, but when taken with isoniazid, they team up to damage mitochondria—the cell's power plants—causing toxic stress. The study proves this combo is dangerous because it breaks the energy system in a way that only happens when both drugs are present.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.